NEW YORK (GenomeWeb) – Response Genetics' first quarter revenues dropped 30 percent year over year despite an increase in its ResponseDX revenues, the company said today.

For the three months ended March 31, total revenues fell to $3.9 million from $5.6 million a year ago. ResponseDX revenues were up about 4 percent year over year to $3.3 million, but revenues from its pharmaceutical clients shrank by $1.9 million, Response said, due to the timing of services performed for the firm's largest pharma client.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.